EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Autologous platelet concentrates as adjuvant in the surgical management of medication‐related osteonecrosis of the jaw

Francesco Bennardo, Selene Barone, Alessandro Antonelli, Amerigo Giudice

Periodontology 2000 · 2025

DOI: 10.1111/prd.12608 ↗

At a glance

Übersichtsarbeit in Periodontology 2000, 2025. Written by Francesco Bennardo and 3 co-authors. Institution: School of Dentistry, Magna Graecia University of Catanzaro, Catanzaro, Italy. Major MEDLINE topics: Bisphosphonate-Associated Osteonecrosis of the Jaw, Platelet-Rich Plasma, Platelet Transfusion. Cited 25 times so far (Crossref); 101 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Medication‐related osteonecrosis of the jaw (MRONJ) is an infectious side effect associated with bisphosphonates and monoclonal antibodies (denosumab, immune modulators, and antiangiogenic medications). Adjunctive therapies for the surgical management of MRONJ include autologous platelet concentrates (APCs). These APCs serve as a source of various cells and growth factors that aid tissue healing and regeneration. This review evaluated the use of platelet‐rich plasma (PRP), plasma‐rich in growth factors (PRGF), and leukocyte‐ and platelet‐rich fibrin (L‐PRF) as adjuvant therapies for the surgical management of MRONJ by conducting analyses on the results of 58 articles. Compared to surgical treatment alone, the application of PRP and L‐PRF after surgery appears to increase healing in the management of patients with MRONJ. No studies have reported unhealed lesions as a result of surgical treatment of MRONJ with PRGF application or compared it with surgical treatment alone. The overall results of this review have shown favorable healing rates of MRONJ lesions managed with the application of APCs after surgical treatment; however, significant methodological limitations may limit the scientific evidence supporting their use. Further randomized controlled trials with strict criteria are needed to establish the extent to which APCs can improve wound healing and quality of life in patients with MRONJ requiring surgical treatment.

Subjects

MeSH terms (MEDLINE)

Bisphosphonate-Associated Osteonecrosis of the JawPlatelet-Rich PlasmaPlatelet TransfusionHumansPlatelet-Rich FibrinWound HealingIntercellular Signaling Peptides and ProteinsCombined Modality Therapy

Author keywords

L‐PRFONJPRGFPRPosteonecrosisplatelet concentratesreview

Substances

Intercellular Signaling Peptides and Proteins

Authors and institutions

  • School of Dentistry, Magna Graecia University of Catanzaro, Catanzaro, Italy.

Cite

APA

Bennardo, F., Barone, S., Antonelli, A., & Giudice, A. (2025). Autologous platelet concentrates as adjuvant in the surgical management of medication‐related osteonecrosis of the jaw. Periodontology 2000. https://doi.org/10.1111/prd.12608

Vancouver

Bennardo F, Barone S, Antonelli A, Giudice A. Autologous platelet concentrates as adjuvant in the surgical management of medication‐related osteonecrosis of the jaw. Periodontology 2000. 2025. doi:10.1111/prd.12608

BibTeX
@article{Bennardo2025,
  author = {Bennardo, Francesco and Barone, Selene and Antonelli, Alessandro and Giudice, Amerigo},
  title = {Autologous platelet concentrates as adjuvant in the surgical management of medication‐related osteonecrosis of the jaw},
  journal = {Periodontology 2000},
  year = {2025},
  doi = {10.1111/prd.12608}
}
Start for free →